The LAKANA trial sub-study, published in PLOS Medicine, assessed antimicrobial resistance (AMR) following mass azithromycin administration in infants aged 1 to 11 months across 59 villages in Mali.Children received placebo, twice-yearly azithromycin, or quarterly azithromycin for two years. Researchers analysed 5,025 nasopharyngeal and 5,021 rectal samples to assess resistance in Streptococcus pneumoniae and Escherichia coli. At 36 months, macrolide resistance in S. pneumoniae was 13.4% with placebo, 14.5% with twice-yearly dosing, and 17.2% with quarterly dosing.

Corresponding E. coli resistance rates were 5.1%, 6.4%, and 9.1%.Twice-yearly administration met the predefined noninferiority margin for resistance outcomes. However, quarterly dosing could not exclude a modest increase in resistance in both organisms. No marked differences were observed among untreated older contacts.โ€ฆ